Skip to main content
ITRMF logo

ITRMF · Iterum Therapeutics plc

$0.03 +0.00 (+0.00%) At close · Jul 23
Market Cap
$1.38M
Shares
44.66M

Iterum Therapeutics plc Earnings Call Transcripts

Every quarterly earnings call for Iterum Therapeutics plc (ITRMF) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Earnings call
FY25 · Q3
2025-11-14
Iterum Therapeutics plc Q3 FY2025 Earnings Call
Positive tone Orlynda Commercial Launch Sales Force / Field Operations Specialty Distribution Partners
Revenue
$390,000
Diluted EPS
$-0.20
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-05
Iterum Therapeutics plc Q2 FY2025 Earnings Call
Confident tone ORLYNVAH Commercial Launch Market Opportunity and Unmet Need Commercial Strategy and Sales Coverage
Diluted EPS
$-0.16
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-13
Iterum Therapeutics plc Q1 FY2025 Earnings Call
Positive tone ORLYNVAH launch and commercialization Competition Market opportunity and unmet need
Diluted EPS
$-0.14
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-07
Iterum Therapeutics plc Q4 FY2024 Earnings Call
Positive tone FDA approval and ORLYNVAH launch readiness Cash runway and going concern Uncomplicated urinary tract infection market opportunity
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-14
Iterum Therapeutics plc Q3 FY2024 Earnings Call
Confident tone Cash runway and exchangeable notes Intellectual property and market exclusivity Strategic alternatives / partnership process
Diluted EPS
$-0.30
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-14
Iterum Therapeutics plc Q2 FY2024 Earnings Call
Positive tone FDA Advisory Committee and PDUFA Capital and Cash Runway Antibiotic Stewardship and Label
Diluted EPS
$-0.30
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-13
Iterum Therapeutics plc Q1 FY2024 Earnings Call
Confident tone FDA resubmission and review of oral sulopenem NDA Cash runway and financial position Market positioning and competition for uncomplicated UTIs
Diluted EPS
$-0.46
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-29
Iterum Therapeutics plc Q4 FY2023 Earnings Call
Confident tone NDA resubmission and FDA review Financial position and cash runway Uncomplicated UTI market opportunity
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-14
Iterum Therapeutics plc Q3 FY2023 Earnings Call
Diluted EPS
$-0.30
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-11
Iterum Therapeutics plc Q2 FY2023 Earnings Call
Diluted EPS
$-0.95
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-16
Iterum Therapeutics plc Q4 FY2022 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-10
Iterum Therapeutics plc Q3 FY2022 Earnings Call
Diluted EPS
$-2.38
▼ 893.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-28
Iterum Therapeutics plc Q4 FY2021 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-12
Iterum Therapeutics plc Q3 FY2021 Earnings Call
Diluted EPS
$0.30
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-13
Iterum Therapeutics plc Q2 FY2021 Earnings Call
Diluted EPS
$0.60
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-14
Iterum Therapeutics plc Q1 FY2021 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-12
Iterum Therapeutics plc Q4 FY2020 Earnings Call
Revenue
$*
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–17 of 17 earnings calls
Key facts CIK 1659323 CUSIP G6333L200 13F (30d) 2 filings 1 filers Visit website Investor relations